| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreas Transplantation | 208 | 2020 | 245 | 23.750 |
Why?
|
| Kidney Transplantation | 229 | 2020 | 490 | 22.150 |
Why?
|
| Graft Rejection | 125 | 2019 | 236 | 8.960 |
Why?
|
| Tissue Donors | 58 | 2018 | 186 | 7.610 |
Why?
|
| Immunosuppressive Agents | 82 | 2019 | 248 | 7.100 |
Why?
|
| Graft Survival | 117 | 2020 | 293 | 5.950 |
Why?
|
| Tissue and Organ Procurement | 37 | 2018 | 88 | 4.470 |
Why?
|
| Diabetes Mellitus, Type 1 | 69 | 2020 | 267 | 4.220 |
Why?
|
| Immunosuppression | 56 | 2019 | 118 | 3.470 |
Why?
|
| Antilymphocyte Serum | 29 | 2015 | 40 | 3.460 |
Why?
|
| Liver Transplantation | 80 | 2020 | 185 | 3.380 |
Why?
|
| Antibodies, Monoclonal | 32 | 2009 | 245 | 3.050 |
Why?
|
| Humans | 389 | 2020 | 32282 | 2.730 |
Why?
|
| Adult | 218 | 2020 | 9259 | 2.650 |
Why?
|
| Postoperative Complications | 69 | 2020 | 823 | 2.490 |
Why?
|
| Delayed Graft Function | 9 | 2020 | 29 | 2.410 |
Why?
|
| Retrospective Studies | 111 | 2020 | 3626 | 2.390 |
Why?
|
| Kidney Failure, Chronic | 19 | 2018 | 534 | 2.370 |
Why?
|
| Immunoglobulin G | 17 | 2005 | 129 | 2.070 |
Why?
|
| Male | 203 | 2020 | 19441 | 1.980 |
Why?
|
| Drainage | 23 | 2013 | 65 | 1.940 |
Why?
|
| Female | 203 | 2020 | 19945 | 1.930 |
Why?
|
| Organ Preservation | 30 | 2014 | 37 | 1.900 |
Why?
|
| Middle Aged | 145 | 2020 | 11851 | 1.890 |
Why?
|
| Survival Rate | 55 | 2020 | 893 | 1.830 |
Why?
|
| Cytomegalovirus Infections | 23 | 2014 | 47 | 1.790 |
Why?
|
| Follow-Up Studies | 65 | 2019 | 2240 | 1.770 |
Why?
|
| Kidney | 25 | 2020 | 521 | 1.660 |
Why?
|
| Time Factors | 70 | 2020 | 2205 | 1.660 |
Why?
|
| Tacrolimus | 30 | 2008 | 66 | 1.600 |
Why?
|
| Islets of Langerhans Transplantation | 11 | 2020 | 46 | 1.570 |
Why?
|
| Mycophenolic Acid | 18 | 2008 | 42 | 1.480 |
Why?
|
| Donor Selection | 4 | 2019 | 28 | 1.450 |
Why?
|
| Portal Vein | 14 | 2013 | 27 | 1.410 |
Why?
|
| Cadaver | 30 | 2018 | 151 | 1.410 |
Why?
|
| Pancreas | 25 | 2020 | 107 | 1.390 |
Why?
|
| Diabetes Mellitus | 22 | 2015 | 390 | 1.370 |
Why?
|
| Diabetic Nephropathies | 28 | 2008 | 223 | 1.320 |
Why?
|
| Transplantation, Homologous | 43 | 2014 | 158 | 1.320 |
Why?
|
| Tissue and Organ Harvesting | 7 | 2014 | 35 | 1.320 |
Why?
|
| Renal Insufficiency | 6 | 2020 | 57 | 1.210 |
Why?
|
| Organ Transplantation | 10 | 2013 | 67 | 1.190 |
Why?
|
| Treatment Outcome | 52 | 2017 | 3416 | 1.180 |
Why?
|
| Regenerative Medicine | 12 | 2015 | 217 | 1.160 |
Why?
|
| Patient Selection | 18 | 2018 | 272 | 1.130 |
Why?
|
| Regeneration | 10 | 2016 | 178 | 1.080 |
Why?
|
| Risk Factors | 53 | 2018 | 3934 | 0.980 |
Why?
|
| C-Peptide | 7 | 2018 | 31 | 0.980 |
Why?
|
| Nephrectomy | 6 | 2019 | 123 | 0.980 |
Why?
|
| Living Donors | 11 | 2015 | 61 | 0.890 |
Why?
|
| Tissue Engineering | 10 | 2016 | 695 | 0.890 |
Why?
|
| Antiviral Agents | 11 | 2010 | 107 | 0.830 |
Why?
|
| Antibodies, Neoplasm | 4 | 2009 | 16 | 0.820 |
Why?
|
| Azathioprine | 17 | 2011 | 27 | 0.790 |
Why?
|
| Aged | 41 | 2020 | 10263 | 0.760 |
Why?
|
| Radiography, Interventional | 2 | 2014 | 32 | 0.750 |
Why?
|
| Ganciclovir | 13 | 2008 | 23 | 0.750 |
Why?
|
| Tissue Scaffolds | 12 | 2016 | 431 | 0.730 |
Why?
|
| Adolescent | 41 | 2019 | 3519 | 0.720 |
Why?
|
| Isoantibodies | 5 | 2014 | 11 | 0.700 |
Why?
|
| Incidence | 23 | 2018 | 1241 | 0.700 |
Why?
|
| Registries | 6 | 2016 | 294 | 0.700 |
Why?
|
| Survival Analysis | 23 | 2019 | 477 | 0.680 |
Why?
|
| Extracellular Matrix | 9 | 2016 | 256 | 0.670 |
Why?
|
| Liver Failure | 3 | 2020 | 21 | 0.670 |
Why?
|
| Reoperation | 25 | 2019 | 252 | 0.670 |
Why?
|
| Bioengineering | 9 | 2015 | 77 | 0.650 |
Why?
|
| Prognosis | 16 | 2018 | 1534 | 0.650 |
Why?
|
| Prospective Studies | 22 | 2018 | 2316 | 0.650 |
Why?
|
| Cold Ischemia | 2 | 2018 | 6 | 0.630 |
Why?
|
| Extracorporeal Circulation | 4 | 2011 | 12 | 0.630 |
Why?
|
| Child | 48 | 2019 | 2435 | 0.600 |
Why?
|
| Steroids | 4 | 2015 | 35 | 0.590 |
Why?
|
| Portal System | 8 | 2008 | 13 | 0.590 |
Why?
|
| Thrombosis | 9 | 2014 | 78 | 0.580 |
Why?
|
| Renal Artery | 3 | 2018 | 47 | 0.580 |
Why?
|
| Kidney Diseases | 6 | 2015 | 243 | 0.570 |
Why?
|
| Endarterectomy | 1 | 2018 | 7 | 0.560 |
Why?
|
| Prednisone | 19 | 2002 | 69 | 0.560 |
Why?
|
| Health Services Accessibility | 3 | 2017 | 242 | 0.550 |
Why?
|
| Age Factors | 15 | 2019 | 1179 | 0.540 |
Why?
|
| Carcinoma, Renal Cell | 4 | 2019 | 113 | 0.520 |
Why?
|
| Creatinine | 15 | 2016 | 191 | 0.520 |
Why?
|
| Muromonab-CD3 | 14 | 2002 | 16 | 0.520 |
Why?
|
| North Carolina | 8 | 2018 | 1300 | 0.510 |
Why?
|
| Kidney Neoplasms | 4 | 2019 | 200 | 0.490 |
Why?
|
| Animals | 24 | 2015 | 8199 | 0.480 |
Why?
|
| Young Adult | 10 | 2019 | 2649 | 0.470 |
Why?
|
| Drug Administration Schedule | 11 | 2014 | 276 | 0.470 |
Why?
|
| Drug Therapy, Combination | 19 | 2005 | 292 | 0.460 |
Why?
|
| Kidney Function Tests | 7 | 2018 | 101 | 0.460 |
Why?
|
| Glomerular Filtration Rate | 8 | 2018 | 302 | 0.460 |
Why?
|
| Length of Stay | 10 | 2014 | 321 | 0.460 |
Why?
|
| Child, Preschool | 28 | 2019 | 1233 | 0.450 |
Why?
|
| Embolization, Therapeutic | 2 | 2019 | 81 | 0.440 |
Why?
|
| Uremia | 1 | 2015 | 9 | 0.440 |
Why?
|
| Cyclosporine | 18 | 2001 | 48 | 0.440 |
Why?
|
| Duodenum | 14 | 2001 | 21 | 0.430 |
Why?
|
| Transplantation Conditioning | 1 | 2014 | 23 | 0.430 |
Why?
|
| Acyclovir | 6 | 1998 | 14 | 0.430 |
Why?
|
| Cyclosporins | 17 | 1991 | 22 | 0.420 |
Why?
|
| Death | 3 | 2009 | 51 | 0.420 |
Why?
|
| Perfusion | 7 | 2015 | 75 | 0.420 |
Why?
|
| Ossification, Heterotopic | 1 | 2014 | 21 | 0.420 |
Why?
|
| Polyomavirus Infections | 5 | 2006 | 20 | 0.410 |
Why?
|
| Insulin | 16 | 2018 | 359 | 0.400 |
Why?
|
| Gastrointestinal Tract | 3 | 2012 | 40 | 0.400 |
Why?
|
| Histocompatibility Testing | 13 | 2014 | 25 | 0.390 |
Why?
|
| Rabbits | 5 | 2014 | 219 | 0.390 |
Why?
|
| Biopsy | 12 | 2014 | 252 | 0.380 |
Why?
|
| African Americans | 10 | 2016 | 1335 | 0.370 |
Why?
|
| United States | 13 | 2017 | 4072 | 0.370 |
Why?
|
| Preoperative Care | 2 | 2014 | 125 | 0.360 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2020 | 71 | 0.360 |
Why?
|
| Blood Transfusion | 8 | 2014 | 69 | 0.360 |
Why?
|
| Catheter Ablation | 1 | 2013 | 113 | 0.350 |
Why?
|
| Transplantation Tolerance | 1 | 2011 | 14 | 0.350 |
Why?
|
| Hypoglycemia | 3 | 1998 | 43 | 0.350 |
Why?
|
| Fibrinolytic Agents | 1 | 2012 | 63 | 0.350 |
Why?
|
| Infant | 24 | 2019 | 1010 | 0.350 |
Why?
|
| Gout | 1 | 2011 | 13 | 0.350 |
Why?
|
| Cytomegalovirus | 4 | 2005 | 26 | 0.350 |
Why?
|
| Thiazoles | 1 | 2011 | 36 | 0.340 |
Why?
|
| Lipids | 5 | 1999 | 253 | 0.340 |
Why?
|
| Thrombectomy | 1 | 2012 | 74 | 0.340 |
Why?
|
| Anticoagulants | 2 | 2012 | 122 | 0.340 |
Why?
|
| Urinary Bladder | 11 | 2005 | 320 | 0.340 |
Why?
|
| Opportunistic Infections | 5 | 1998 | 19 | 0.330 |
Why?
|
| Heart Arrest | 1 | 2011 | 42 | 0.330 |
Why?
|
| Pyelonephritis | 1 | 2010 | 9 | 0.330 |
Why?
|
| Emphysema | 1 | 2010 | 12 | 0.320 |
Why?
|
| Pancreatectomy | 3 | 1999 | 25 | 0.320 |
Why?
|
| Lipoproteins, HDL | 6 | 2016 | 250 | 0.320 |
Why?
|
| Sirolimus | 3 | 2008 | 34 | 0.320 |
Why?
|
| Apolipoproteins | 4 | 2016 | 194 | 0.300 |
Why?
|
| Intestines | 7 | 2010 | 63 | 0.300 |
Why?
|
| Waiting Lists | 6 | 2013 | 34 | 0.290 |
Why?
|
| ABO Blood-Group System | 4 | 2016 | 17 | 0.290 |
Why?
|
| Blood Group Incompatibility | 3 | 2016 | 8 | 0.290 |
Why?
|
| Quality of Life | 15 | 2015 | 964 | 0.280 |
Why?
|
| Antibodies | 2 | 1998 | 56 | 0.280 |
Why?
|
| Tumor Virus Infections | 3 | 2004 | 21 | 0.270 |
Why?
|
| Hospital Charges | 2 | 1997 | 15 | 0.270 |
Why?
|
| Bacteremia | 1 | 2008 | 66 | 0.260 |
Why?
|
| Diabetes Mellitus, Type 2 | 6 | 2011 | 1437 | 0.260 |
Why?
|
| European Continental Ancestry Group | 7 | 2015 | 1076 | 0.250 |
Why?
|
| Acute Disease | 10 | 2012 | 253 | 0.250 |
Why?
|
| Anastomosis, Surgical | 8 | 2003 | 58 | 0.250 |
Why?
|
| Nervous System Diseases | 1 | 2007 | 46 | 0.250 |
Why?
|
| Organ Preservation Solutions | 6 | 1993 | 8 | 0.250 |
Why?
|
| Neurons, Afferent | 1 | 2007 | 64 | 0.250 |
Why?
|
| Adrenal Cortex Hormones | 5 | 2005 | 116 | 0.240 |
Why?
|
| Postoperative Period | 4 | 2014 | 95 | 0.240 |
Why?
|
| Stem Cell Transplantation | 5 | 2015 | 221 | 0.240 |
Why?
|
| Anemia, Hemolytic | 1 | 2005 | 8 | 0.230 |
Why?
|
| Erythrocytes | 1 | 2005 | 41 | 0.230 |
Why?
|
| Methylprednisolone | 3 | 1999 | 14 | 0.230 |
Why?
|
| Cohort Studies | 5 | 2011 | 1840 | 0.230 |
Why?
|
| Solutions | 8 | 2009 | 40 | 0.220 |
Why?
|
| Liver | 10 | 2012 | 492 | 0.210 |
Why?
|
| Hypertension | 1 | 2011 | 979 | 0.210 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2002 | 99 | 0.210 |
Why?
|
| Octreotide | 2 | 1993 | 6 | 0.210 |
Why?
|
| Cholesterol | 6 | 2004 | 262 | 0.200 |
Why?
|
| T-Lymphocytes | 3 | 2009 | 140 | 0.200 |
Why?
|
| Treatment Failure | 4 | 2017 | 165 | 0.200 |
Why?
|
| Hepatitis, Viral, Human | 3 | 1994 | 6 | 0.200 |
Why?
|
| Nephritis, Interstitial | 1 | 2003 | 9 | 0.190 |
Why?
|
| HLA Antigens | 5 | 2014 | 40 | 0.190 |
Why?
|
| Hepatitis C | 2 | 2019 | 47 | 0.190 |
Why?
|
| Academic Medical Centers | 2 | 2003 | 161 | 0.180 |
Why?
|
| Amylases | 7 | 1997 | 10 | 0.180 |
Why?
|
| Odds Ratio | 4 | 2016 | 456 | 0.180 |
Why?
|
| Multivariate Analysis | 7 | 2017 | 651 | 0.170 |
Why?
|
| Arteriosclerosis | 3 | 1996 | 147 | 0.170 |
Why?
|
| Renal Dialysis | 8 | 2001 | 276 | 0.170 |
Why?
|
| Antifungal Agents | 2 | 1998 | 45 | 0.160 |
Why?
|
| Chi-Square Distribution | 3 | 2017 | 287 | 0.160 |
Why?
|
| Tennessee | 5 | 2002 | 98 | 0.160 |
Why?
|
| Midodrine | 1 | 2000 | 1 | 0.160 |
Why?
|
| Hypotension, Orthostatic | 1 | 2000 | 12 | 0.160 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2000 | 43 | 0.150 |
Why?
|
| Glucocorticoids | 3 | 2001 | 146 | 0.150 |
Why?
|
| Intestine, Small | 1 | 2000 | 43 | 0.150 |
Why?
|
| Blood Glucose | 8 | 1998 | 484 | 0.150 |
Why?
|
| Cause of Death | 5 | 2007 | 236 | 0.150 |
Why?
|
| RNA | 1 | 2020 | 94 | 0.150 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 3900 | 0.150 |
Why?
|
| Health Care Rationing | 1 | 1999 | 11 | 0.150 |
Why?
|
| Transplantation Immunology | 5 | 2015 | 30 | 0.150 |
Why?
|
| Patient Readmission | 3 | 2001 | 135 | 0.150 |
Why?
|
| Hemodynamics | 2 | 2015 | 164 | 0.150 |
Why?
|
| Islets of Langerhans | 3 | 2016 | 73 | 0.140 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 315 | 0.140 |
Why?
|
| Actuarial Analysis | 9 | 1994 | 12 | 0.140 |
Why?
|
| Biopsy, Needle | 3 | 1997 | 95 | 0.140 |
Why?
|
| Fluconazole | 1 | 1998 | 8 | 0.140 |
Why?
|
| Triglycerides | 6 | 2004 | 235 | 0.130 |
Why?
|
| Renal Replacement Therapy | 1 | 1997 | 18 | 0.130 |
Why?
|
| Hematuria | 4 | 1995 | 10 | 0.130 |
Why?
|
| Immune Tolerance | 4 | 2014 | 66 | 0.130 |
Why?
|
| Critical Pathways | 1 | 1997 | 47 | 0.130 |
Why?
|
| Immunization, Passive | 5 | 2002 | 9 | 0.130 |
Why?
|
| Managed Care Programs | 1 | 1997 | 43 | 0.130 |
Why?
|
| Antibody Formation | 3 | 2002 | 47 | 0.130 |
Why?
|
| Ethnic Groups | 2 | 2013 | 450 | 0.130 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 4 | 1992 | 9 | 0.120 |
Why?
|
| Bioreactors | 2 | 2013 | 58 | 0.120 |
Why?
|
| Receptors, Antigen, T-Cell | 4 | 1992 | 31 | 0.120 |
Why?
|
| Mesenteric Veins | 4 | 2000 | 10 | 0.120 |
Why?
|
| Infection Control | 1 | 1995 | 26 | 0.120 |
Why?
|
| Carotid Artery, Common | 1 | 1995 | 48 | 0.120 |
Why?
|
| Microvessels | 1 | 2015 | 30 | 0.110 |
Why?
|
| Kidney Glomerulus | 1 | 2015 | 28 | 0.110 |
Why?
|
| Age of Onset | 2 | 2008 | 90 | 0.110 |
Why?
|
| Healthcare Disparities | 1 | 2017 | 180 | 0.110 |
Why?
|
| Caveolin 1 | 1 | 2015 | 13 | 0.110 |
Why?
|
| Immunocompromised Host | 3 | 2002 | 53 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2005 | 717 | 0.110 |
Why?
|
| Biliary Tract Diseases | 4 | 1992 | 12 | 0.110 |
Why?
|
| Brain Death | 2 | 2014 | 23 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 2 | 2010 | 191 | 0.110 |
Why?
|
| Preoperative Period | 1 | 2014 | 30 | 0.110 |
Why?
|
| Pravastatin | 1 | 1994 | 16 | 0.110 |
Why?
|
| Burns | 3 | 1985 | 102 | 0.110 |
Why?
|
| Kidney Tubular Necrosis, Acute | 2 | 1992 | 3 | 0.110 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2015 | 100 | 0.110 |
Why?
|
| Ischemia | 3 | 2009 | 115 | 0.110 |
Why?
|
| Cholecystectomy | 3 | 1997 | 21 | 0.110 |
Why?
|
| Insulin Antibodies | 1 | 1994 | 2 | 0.110 |
Why?
|
| Survivors | 2 | 2008 | 173 | 0.110 |
Why?
|
| Hospitals, University | 4 | 2000 | 27 | 0.110 |
Why?
|
| Disease-Free Survival | 4 | 2002 | 324 | 0.110 |
Why?
|
| Metaplasia | 1 | 2014 | 20 | 0.110 |
Why?
|
| Blood Loss, Surgical | 1 | 2014 | 50 | 0.110 |
Why?
|
| Sex Characteristics | 2 | 1994 | 173 | 0.100 |
Why?
|
| Cystoscopy | 1 | 1994 | 27 | 0.100 |
Why?
|
| Apolipoproteins B | 1 | 1994 | 48 | 0.100 |
Why?
|
| Disease Progression | 2 | 2014 | 591 | 0.100 |
Why?
|
| Cholesterol, LDL | 1 | 1994 | 170 | 0.100 |
Why?
|
| Insulin-Secreting Cells | 1 | 2014 | 49 | 0.100 |
Why?
|
| Diet | 1 | 1996 | 383 | 0.100 |
Why?
|
| Liver Diseases | 7 | 2000 | 72 | 0.100 |
Why?
|
| Apolipoprotein A-I | 1 | 1994 | 64 | 0.100 |
Why?
|
| Diabetes Complications | 3 | 2010 | 171 | 0.100 |
Why?
|
| Genetic Variation | 1 | 2015 | 248 | 0.100 |
Why?
|
| Ultrasonography, Interventional | 1 | 1994 | 55 | 0.100 |
Why?
|
| Bioprosthesis | 1 | 2014 | 60 | 0.100 |
Why?
|
| Regional Blood Flow | 1 | 2013 | 85 | 0.100 |
Why?
|
| Organ Culture Techniques | 1 | 2013 | 44 | 0.100 |
Why?
|
| Proportional Hazards Models | 4 | 2017 | 773 | 0.100 |
Why?
|
| Duodenal Diseases | 3 | 1997 | 4 | 0.100 |
Why?
|
| Intraoperative Complications | 3 | 2005 | 55 | 0.100 |
Why?
|
| Mycoses | 6 | 1993 | 20 | 0.100 |
Why?
|
| Surgical Wound Infection | 3 | 1992 | 99 | 0.090 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 1992 | 24 | 0.090 |
Why?
|
| Insurance Coverage | 1 | 2013 | 80 | 0.090 |
Why?
|
| Abdomen | 1 | 2012 | 44 | 0.090 |
Why?
|
| Cells, Cultured | 1 | 2014 | 839 | 0.090 |
Why?
|
| Hyperglycemia | 3 | 2010 | 85 | 0.090 |
Why?
|
| Case-Control Studies | 5 | 2007 | 854 | 0.090 |
Why?
|
| Blood Grouping and Crossmatching | 2 | 2016 | 6 | 0.090 |
Why?
|
| Leukopenia | 2 | 2008 | 9 | 0.090 |
Why?
|
| Warfarin | 1 | 2012 | 32 | 0.090 |
Why?
|
| Leukocyte Count | 3 | 2005 | 46 | 0.090 |
Why?
|
| Renal Veins | 2 | 1988 | 7 | 0.090 |
Why?
|
| Postoperative Hemorrhage | 1 | 2012 | 38 | 0.090 |
Why?
|
| Cold Temperature | 5 | 2001 | 56 | 0.090 |
Why?
|
| Aspirin | 1 | 2012 | 59 | 0.090 |
Why?
|
| Gout Suppressants | 1 | 2011 | 4 | 0.090 |
Why?
|
| Heparin | 1 | 2012 | 65 | 0.090 |
Why?
|
| Gastrointestinal Diseases | 1 | 2012 | 50 | 0.090 |
Why?
|
| Genotype | 4 | 2016 | 702 | 0.090 |
Why?
|
| Drug Interactions | 1 | 2011 | 86 | 0.090 |
Why?
|
| General Surgery | 1 | 2012 | 84 | 0.090 |
Why?
|
| Warm Ischemia | 1 | 2011 | 9 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 1050 | 0.090 |
Why?
|
| Autoantibodies | 1 | 2011 | 50 | 0.080 |
Why?
|
| Proinsulin | 3 | 1997 | 11 | 0.080 |
Why?
|
| Attitude to Health | 3 | 2011 | 138 | 0.080 |
Why?
|
| Bile Ducts | 2 | 2001 | 19 | 0.080 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2001 | 120 | 0.080 |
Why?
|
| Pancreatic Diseases | 3 | 2012 | 21 | 0.080 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2010 | 13 | 0.080 |
Why?
|
| Serum Albumin | 2 | 2010 | 56 | 0.080 |
Why?
|
| Ultrasonography | 7 | 1995 | 393 | 0.080 |
Why?
|
| Asphyxia | 2 | 2009 | 8 | 0.080 |
Why?
|
| Immunotherapy | 1 | 2010 | 91 | 0.080 |
Why?
|
| Urine | 4 | 1997 | 69 | 0.080 |
Why?
|
| Nephrotic Syndrome | 1 | 2009 | 11 | 0.080 |
Why?
|
| Stem Cells | 4 | 2014 | 321 | 0.080 |
Why?
|
| Blood Pressure | 4 | 2010 | 861 | 0.080 |
Why?
|
| Jejunostomy | 3 | 2001 | 8 | 0.080 |
Why?
|
| Risk Assessment | 2 | 2017 | 1425 | 0.080 |
Why?
|
| Antigens, Surface | 2 | 1988 | 25 | 0.080 |
Why?
|
| Regression Analysis | 3 | 2005 | 273 | 0.070 |
Why?
|
| African Continental Ancestry Group | 2 | 2008 | 338 | 0.070 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2009 | 6 | 0.070 |
Why?
|
| Molecular Motor Proteins | 1 | 2009 | 59 | 0.070 |
Why?
|
| Infarction | 1 | 2009 | 7 | 0.070 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1989 | 5 | 0.070 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 1989 | 8 | 0.070 |
Why?
|
| Myosin Heavy Chains | 1 | 2009 | 84 | 0.070 |
Why?
|
| Suicide | 1 | 2009 | 19 | 0.070 |
Why?
|
| Hepatic Artery | 5 | 1992 | 14 | 0.070 |
Why?
|
| Sepsis | 1 | 2010 | 164 | 0.070 |
Why?
|
| Colonic Pseudo-Obstruction | 1 | 1988 | 2 | 0.070 |
Why?
|
| Compartment Syndromes | 1 | 2009 | 36 | 0.070 |
Why?
|
| Polyomavirus | 2 | 2006 | 2 | 0.070 |
Why?
|
| Intestinal Pseudo-Obstruction | 1 | 1988 | 4 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2011 | 541 | 0.070 |
Why?
|
| Anastomosis, Roux-en-Y | 3 | 2001 | 6 | 0.070 |
Why?
|
| Costs and Cost Analysis | 4 | 1998 | 106 | 0.070 |
Why?
|
| Hepatectomy | 3 | 2001 | 57 | 0.070 |
Why?
|
| Inflammation | 1 | 2012 | 506 | 0.070 |
Why?
|
| Sex Factors | 5 | 2008 | 655 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 1 | 2011 | 395 | 0.070 |
Why?
|
| Predictive Value of Tests | 3 | 2008 | 883 | 0.070 |
Why?
|
| Lymphocytes | 2 | 2005 | 56 | 0.070 |
Why?
|
| T-Lymphocyte Subsets | 3 | 1994 | 24 | 0.070 |
Why?
|
| Cholesterol, HDL | 4 | 1999 | 181 | 0.070 |
Why?
|
| Cryopreservation | 2 | 2007 | 52 | 0.070 |
Why?
|
| Herpesviridae Infections | 3 | 1994 | 7 | 0.070 |
Why?
|
| Administration, Oral | 2 | 1998 | 200 | 0.070 |
Why?
|
| Bacteria | 1 | 2008 | 54 | 0.070 |
Why?
|
| Immunoglobulins | 2 | 2002 | 13 | 0.070 |
Why?
|
| Hemolysis | 2 | 2005 | 11 | 0.070 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1988 | 76 | 0.070 |
Why?
|
| Intraoperative Period | 1 | 2007 | 43 | 0.070 |
Why?
|
| Age Distribution | 1 | 2007 | 194 | 0.060 |
Why?
|
| Plasma Exchange | 2 | 1984 | 13 | 0.060 |
Why?
|
| Haplotypes | 3 | 2015 | 213 | 0.060 |
Why?
|
| Bacterial Infections | 4 | 2001 | 45 | 0.060 |
Why?
|
| Antibiotic Prophylaxis | 3 | 2001 | 40 | 0.060 |
Why?
|
| Raffinose | 6 | 1993 | 6 | 0.060 |
Why?
|
| Body Size | 1 | 2006 | 35 | 0.060 |
Why?
|
| Allopurinol | 6 | 1993 | 13 | 0.060 |
Why?
|
| Monitoring, Physiologic | 4 | 2001 | 77 | 0.060 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2001 | 6 | 0.060 |
Why?
|
| Safety | 2 | 1997 | 65 | 0.060 |
Why?
|
| Glutathione | 6 | 1993 | 54 | 0.060 |
Why?
|
| Adenosine | 6 | 1993 | 68 | 0.060 |
Why?
|
| Nephrons | 1 | 2006 | 10 | 0.060 |
Why?
|
| Pulmonary Edema | 2 | 1996 | 12 | 0.060 |
Why?
|
| Nebraska | 4 | 1994 | 6 | 0.060 |
Why?
|
| Rho(D) Immune Globulin | 1 | 2005 | 1 | 0.060 |
Why?
|
| Glycosuria, Renal | 1 | 2005 | 2 | 0.060 |
Why?
|
| Arteries | 2 | 1998 | 75 | 0.060 |
Why?
|
| Glucose | 2 | 1998 | 160 | 0.060 |
Why?
|
| Organogenesis | 2 | 2016 | 18 | 0.060 |
Why?
|
| Heart Diseases | 2 | 2005 | 114 | 0.060 |
Why?
|
| Diabetic Neuropathies | 2 | 2000 | 28 | 0.060 |
Why?
|
| Lymphocyte Count | 1 | 2005 | 25 | 0.060 |
Why?
|
| Diabetic Angiopathies | 2 | 1996 | 150 | 0.060 |
Why?
|
| Mesenteric Arteries | 2 | 1996 | 20 | 0.060 |
Why?
|
| Receptors, Interleukin-2 | 2 | 2001 | 7 | 0.060 |
Why?
|
| Glucagon | 3 | 1994 | 5 | 0.060 |
Why?
|
| Quality of Health Care | 1 | 2006 | 148 | 0.060 |
Why?
|
| Arteriovenous Fistula | 2 | 1996 | 19 | 0.050 |
Why?
|
| Tissue Preservation | 3 | 1989 | 8 | 0.050 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 1985 | 34 | 0.050 |
Why?
|
| Hypertonic Solutions | 4 | 1993 | 4 | 0.050 |
Why?
|
| Drug Monitoring | 1 | 2004 | 30 | 0.050 |
Why?
|
| Surgical Flaps | 1 | 1985 | 76 | 0.050 |
Why?
|
| Virus Diseases | 3 | 1995 | 21 | 0.050 |
Why?
|
| Herpesvirus 4, Human | 3 | 1994 | 8 | 0.050 |
Why?
|
| Hepatitis B | 2 | 2002 | 17 | 0.050 |
Why?
|
| BK Virus | 1 | 2004 | 5 | 0.050 |
Why?
|
| Phenotype | 2 | 2016 | 622 | 0.050 |
Why?
|
| Analysis of Variance | 3 | 1994 | 471 | 0.050 |
Why?
|
| Infant, Newborn | 6 | 1992 | 666 | 0.050 |
Why?
|
| Shock | 1 | 1983 | 34 | 0.050 |
Why?
|
| Postoperative Care | 3 | 2000 | 79 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2005 | 553 | 0.050 |
Why?
|
| Nephritis | 1 | 2003 | 15 | 0.050 |
Why?
|
| Employment | 2 | 1993 | 44 | 0.050 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2003 | 21 | 0.050 |
Why?
|
| Lamivudine | 1 | 2002 | 1 | 0.050 |
Why?
|
| Transplants | 2 | 2014 | 22 | 0.050 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2002 | 5 | 0.050 |
Why?
|
| Continental Population Groups | 1 | 2004 | 228 | 0.050 |
Why?
|
| Liver Regeneration | 2 | 2012 | 23 | 0.050 |
Why?
|
| Catheterization, Central Venous | 2 | 2001 | 62 | 0.050 |
Why?
|
| Rhodococcus equi | 1 | 2002 | 1 | 0.050 |
Why?
|
| Actinomycetales Infections | 1 | 2002 | 2 | 0.050 |
Why?
|
| Clinical Protocols | 2 | 1995 | 77 | 0.040 |
Why?
|
| Lung Diseases | 1 | 2002 | 50 | 0.040 |
Why?
|
| Combined Modality Therapy | 3 | 1994 | 555 | 0.040 |
Why?
|
| Ehrlichiosis | 1 | 2001 | 1 | 0.040 |
Why?
|
| Cholangitis, Sclerosing | 2 | 1991 | 6 | 0.040 |
Why?
|
| Life Support Care | 1 | 2001 | 14 | 0.040 |
Why?
|
| Blood Circulation | 1 | 2001 | 3 | 0.040 |
Why?
|
| Granulocytes | 1 | 2001 | 11 | 0.040 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2001 | 10 | 0.040 |
Why?
|
| Hematoma | 1 | 2001 | 26 | 0.040 |
Why?
|
| Multiple Trauma | 1 | 2001 | 41 | 0.040 |
Why?
|
| Biocompatible Materials | 2 | 2012 | 240 | 0.040 |
Why?
|
| Databases, Factual | 2 | 2017 | 368 | 0.040 |
Why?
|
| Aorta, Thoracic | 1 | 2001 | 81 | 0.040 |
Why?
|
| Lymphocele | 1 | 2000 | 2 | 0.040 |
Why?
|
| Premedication | 2 | 1998 | 15 | 0.040 |
Why?
|
| Long-Term Care | 1 | 2000 | 23 | 0.040 |
Why?
|
| Diagnosis, Differential | 4 | 2001 | 504 | 0.040 |
Why?
|
| Jejunum | 1 | 1999 | 8 | 0.040 |
Why?
|
| Spleen | 2 | 1998 | 84 | 0.040 |
Why?
|
| Iliac Artery | 1 | 2000 | 50 | 0.040 |
Why?
|
| Health Status | 1 | 2001 | 355 | 0.040 |
Why?
|
| Ketoconazole | 2 | 1996 | 5 | 0.040 |
Why?
|
| Remission, Spontaneous | 1 | 2019 | 14 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2019 | 49 | 0.040 |
Why?
|
| Angiography | 1 | 2019 | 76 | 0.040 |
Why?
|
| Hepacivirus | 1 | 2019 | 40 | 0.040 |
Why?
|
| Viral Load | 1 | 2019 | 73 | 0.040 |
Why?
|
| Logistic Models | 1 | 2001 | 743 | 0.040 |
Why?
|
| Cholangiography | 3 | 2001 | 12 | 0.040 |
Why?
|
| Technetium Tc 99m Pentetate | 2 | 1989 | 2 | 0.040 |
Why?
|
| Pentetic Acid | 2 | 1989 | 4 | 0.040 |
Why?
|
| Radionuclide Imaging | 2 | 1989 | 26 | 0.040 |
Why?
|
| Organometallic Compounds | 2 | 1989 | 18 | 0.040 |
Why?
|
| Cystostomy | 2 | 1989 | 5 | 0.040 |
Why?
|
| Vascular Resistance | 3 | 1996 | 32 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2000 | 231 | 0.030 |
Why?
|
| Laparoscopy | 1 | 2000 | 184 | 0.030 |
Why?
|
| Lymphocyte Depletion | 2 | 1988 | 18 | 0.030 |
Why?
|
| Mesenteric Artery, Superior | 1 | 1998 | 9 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 1998 | 99 | 0.030 |
Why?
|
| Platelet Count | 2 | 1994 | 23 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 461 | 0.030 |
Why?
|
| Peritoneal Dialysis | 1 | 1997 | 22 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 1998 | 94 | 0.030 |
Why?
|
| Informed Consent | 1 | 1997 | 44 | 0.030 |
Why?
|
| Lipoproteins, LDL | 2 | 1999 | 99 | 0.030 |
Why?
|
| Carboxypeptidases | 1 | 1997 | 20 | 0.030 |
Why?
|
| Splenectomy | 1 | 1997 | 22 | 0.030 |
Why?
|
| Pancreatitis | 2 | 1993 | 20 | 0.030 |
Why?
|
| Dogs | 3 | 1992 | 126 | 0.030 |
Why?
|
| Risk | 2 | 2011 | 305 | 0.030 |
Why?
|
| Ultrasonography, Doppler | 1 | 1996 | 23 | 0.030 |
Why?
|
| Diet Records | 1 | 1996 | 31 | 0.030 |
Why?
|
| Dietary Carbohydrates | 1 | 1996 | 21 | 0.030 |
Why?
|
| Sodium, Dietary | 1 | 1996 | 22 | 0.030 |
Why?
|
| Dietary Fats | 1 | 1996 | 99 | 0.030 |
Why?
|
| Respiratory Distress Syndrome, Adult | 1 | 1996 | 50 | 0.030 |
Why?
|
| Medicare | 1 | 1997 | 219 | 0.030 |
Why?
|
| Protein Array Analysis | 1 | 2015 | 14 | 0.030 |
Why?
|
| Energy Intake | 1 | 1996 | 122 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 2 | 1993 | 39 | 0.030 |
Why?
|
| Corrosion Casting | 1 | 2015 | 10 | 0.030 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2015 | 22 | 0.030 |
Why?
|
| Social Support | 1 | 2017 | 180 | 0.030 |
Why?
|
| Portasystemic Shunt, Surgical | 2 | 1992 | 4 | 0.030 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2015 | 102 | 0.030 |
Why?
|
| Heart Transplantation | 3 | 2004 | 33 | 0.030 |
Why?
|
| Alabama | 1 | 2015 | 41 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 2 | 1995 | 324 | 0.030 |
Why?
|
| Pancreatic Hormones | 1 | 1994 | 1 | 0.030 |
Why?
|
| Prostate-Specific Antigen | 1 | 1995 | 59 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2015 | 113 | 0.030 |
Why?
|
| Hemoglobins | 1 | 1994 | 45 | 0.030 |
Why?
|
| Necrosis | 3 | 2006 | 54 | 0.030 |
Why?
|
| Lovastatin | 1 | 1994 | 6 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 146 | 0.030 |
Why?
|
| Prolactin | 1 | 1994 | 9 | 0.030 |
Why?
|
| Pancreatic Neoplasms | 1 | 1996 | 131 | 0.030 |
Why?
|
| Ureteral Diseases | 1 | 1994 | 8 | 0.030 |
Why?
|
| Precipitin Tests | 1 | 1994 | 20 | 0.030 |
Why?
|
| Sucrose | 1 | 1994 | 19 | 0.030 |
Why?
|
| Food, Formulated | 1 | 1994 | 13 | 0.030 |
Why?
|
| Liver Function Tests | 5 | 1993 | 22 | 0.030 |
Why?
|
| Menstrual Cycle | 1 | 1994 | 32 | 0.030 |
Why?
|
| Swine | 2 | 2012 | 228 | 0.030 |
Why?
|
| Body Weight | 1 | 1996 | 323 | 0.030 |
Why?
|
| Proteinuria | 2 | 2010 | 52 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1994 | 59 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 907 | 0.030 |
Why?
|
| Hyperlipidemias | 1 | 1994 | 61 | 0.030 |
Why?
|
| Intraoperative Care | 1 | 1994 | 52 | 0.030 |
Why?
|
| Histocompatibility | 2 | 1996 | 7 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 1998 | 1479 | 0.030 |
Why?
|
| Documentation | 1 | 1994 | 39 | 0.030 |
Why?
|
| Forecasting | 1 | 2014 | 144 | 0.030 |
Why?
|
| Cholelithiasis | 1 | 1993 | 10 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 1224 | 0.030 |
Why?
|
| Veins | 1 | 1993 | 34 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 1994 | 184 | 0.030 |
Why?
|
| Chronic Disease | 4 | 2001 | 413 | 0.020 |
Why?
|
| Surgical Mesh | 1 | 1994 | 50 | 0.020 |
Why?
|
| Hypersplenism | 1 | 1993 | 2 | 0.020 |
Why?
|
| Chickens | 1 | 2013 | 36 | 0.020 |
Why?
|
| Detergents | 1 | 2013 | 17 | 0.020 |
Why?
|
| Antigens | 1 | 2013 | 34 | 0.020 |
Why?
|
| Sampling Studies | 1 | 1993 | 42 | 0.020 |
Why?
|
| Wound Infection | 1 | 1993 | 12 | 0.020 |
Why?
|
| Pressure | 1 | 2013 | 69 | 0.020 |
Why?
|
| Sus scrofa | 1 | 2013 | 47 | 0.020 |
Why?
|
| Algorithms | 2 | 1995 | 536 | 0.020 |
Why?
|
| Education | 1 | 1993 | 31 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 2 | 2004 | 72 | 0.020 |
Why?
|
| Choledochal Cyst | 1 | 1992 | 6 | 0.020 |
Why?
|
| Cholestasis, Extrahepatic | 1 | 1992 | 1 | 0.020 |
Why?
|
| Pneumonia | 1 | 1993 | 62 | 0.020 |
Why?
|
| Disabled Persons | 1 | 1993 | 100 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 2 | 2004 | 76 | 0.020 |
Why?
|
| Capsules | 1 | 2012 | 13 | 0.020 |
Why?
|
| Neovascularization, Physiologic | 1 | 2013 | 114 | 0.020 |
Why?
|
| Vascular Diseases | 2 | 1991 | 66 | 0.020 |
Why?
|
| Larynx | 1 | 2012 | 17 | 0.020 |
Why?
|
| Health Surveys | 2 | 2004 | 175 | 0.020 |
Why?
|
| Renal Circulation | 1 | 1992 | 12 | 0.020 |
Why?
|
| Chondroitin Sulfates | 1 | 2012 | 23 | 0.020 |
Why?
|
| Skin, Artificial | 1 | 2012 | 34 | 0.020 |
Why?
|
| Hepatocytes | 1 | 2012 | 80 | 0.020 |
Why?
|
| Respiratory Tract Diseases | 1 | 2012 | 34 | 0.020 |
Why?
|
| Pancreatic Ducts | 2 | 1989 | 6 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2014 | 461 | 0.020 |
Why?
|
| Intestinal Diseases | 1 | 2012 | 17 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 1992 | 68 | 0.020 |
Why?
|
| Cell Transplantation | 1 | 2012 | 65 | 0.020 |
Why?
|
| Intestinal Perforation | 1 | 1991 | 10 | 0.020 |
Why?
|
| Organ Specificity | 2 | 1988 | 80 | 0.020 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2012 | 82 | 0.020 |
Why?
|
| Drug Costs | 1 | 1992 | 46 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 1992 | 65 | 0.020 |
Why?
|
| Developmental Biology | 1 | 2011 | 6 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 545 | 0.020 |
Why?
|
| Drug Evaluation | 2 | 1988 | 15 | 0.020 |
Why?
|
| Cattle | 1 | 2011 | 116 | 0.020 |
Why?
|
| Spouses | 1 | 2011 | 13 | 0.020 |
Why?
|
| HLA-DR6 Antigen | 1 | 1991 | 1 | 0.020 |
Why?
|
| Neoplasms | 1 | 1998 | 754 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2011 | 74 | 0.020 |
Why?
|
| Herpes Simplex | 1 | 1991 | 14 | 0.020 |
Why?
|
| Adenoviridae Infections | 1 | 1991 | 14 | 0.020 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2011 | 36 | 0.020 |
Why?
|
| Recurrence | 3 | 2002 | 285 | 0.020 |
Why?
|
| Collagen | 1 | 2012 | 229 | 0.020 |
Why?
|
| Wound Healing | 1 | 2012 | 185 | 0.020 |
Why?
|
| Chondrocytes | 1 | 2011 | 70 | 0.020 |
Why?
|
| Corneal Transplantation | 1 | 2010 | 14 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2013 | 603 | 0.020 |
Why?
|
| Family | 1 | 2011 | 112 | 0.020 |
Why?
|
| Trachea | 1 | 2010 | 53 | 0.020 |
Why?
|
| Serologic Tests | 1 | 1990 | 11 | 0.020 |
Why?
|
| Ascites | 1 | 1990 | 13 | 0.020 |
Why?
|
| Choledochostomy | 1 | 1989 | 1 | 0.020 |
Why?
|
| Phenoxybenzamine | 1 | 1989 | 2 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2004 | 853 | 0.020 |
Why?
|
| Parents | 1 | 2011 | 151 | 0.020 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 1989 | 29 | 0.020 |
Why?
|
| Wounds and Injuries | 1 | 2012 | 242 | 0.020 |
Why?
|
| Immune Sera | 1 | 1989 | 7 | 0.020 |
Why?
|
| Heart | 1 | 2010 | 177 | 0.020 |
Why?
|
| Aftercare | 1 | 1989 | 35 | 0.020 |
Why?
|
| Transplantation | 1 | 1989 | 12 | 0.020 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2008 | 23 | 0.020 |
Why?
|
| Gastrointestinal Motility | 1 | 1988 | 11 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2010 | 186 | 0.020 |
Why?
|
| Colonoscopy | 1 | 1988 | 45 | 0.020 |
Why?
|
| Technetium | 1 | 1988 | 7 | 0.020 |
Why?
|
| Random Allocation | 1 | 1989 | 247 | 0.020 |
Why?
|
| Lymphocyte Culture Test, Mixed | 2 | 1985 | 7 | 0.020 |
Why?
|
| Models, Biological | 1 | 2010 | 408 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 1989 | 312 | 0.020 |
Why?
|
| Radiography | 3 | 1993 | 363 | 0.020 |
Why?
|
| Drug Therapy | 1 | 2006 | 15 | 0.010 |
Why?
|
| Ohio | 1 | 2005 | 63 | 0.010 |
Why?
|
| Drug Resistance | 3 | 1993 | 42 | 0.010 |
Why?
|
| Mice | 1 | 2011 | 2571 | 0.010 |
Why?
|
| Heart Failure | 1 | 2012 | 728 | 0.010 |
Why?
|
| Fasting | 2 | 1997 | 88 | 0.010 |
Why?
|
| Sensitivity and Specificity | 2 | 1997 | 556 | 0.010 |
Why?
|
| Wisconsin | 3 | 1990 | 21 | 0.010 |
Why?
|
| Disease Management | 1 | 2006 | 129 | 0.010 |
Why?
|
| Needs Assessment | 1 | 2004 | 78 | 0.010 |
Why?
|
| Psychometrics | 1 | 2004 | 137 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2008 | 595 | 0.010 |
Why?
|
| Rupture, Spontaneous | 2 | 1995 | 20 | 0.010 |
Why?
|
| Hepatitis B virus | 1 | 2002 | 5 | 0.010 |
Why?
|
| Chemoprevention | 1 | 2002 | 11 | 0.010 |
Why?
|
| Aging | 1 | 1989 | 942 | 0.010 |
Why?
|
| gamma-Glutamyltransferase | 2 | 1992 | 11 | 0.010 |
Why?
|
| Bilirubin | 2 | 1993 | 23 | 0.010 |
Why?
|
| Alanine Transaminase | 2 | 1992 | 47 | 0.010 |
Why?
|
| Morbidity | 1 | 2002 | 98 | 0.010 |
Why?
|
| Mortality | 1 | 2003 | 122 | 0.010 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2001 | 20 | 0.010 |
Why?
|
| Dissection | 1 | 2001 | 16 | 0.010 |
Why?
|
| False Positive Reactions | 2 | 1993 | 27 | 0.010 |
Why?
|
| Ehrlichia | 1 | 2001 | 1 | 0.010 |
Why?
|
| Retroperitoneal Space | 1 | 2001 | 20 | 0.010 |
Why?
|
| Monitoring, Intraoperative | 1 | 2001 | 40 | 0.010 |
Why?
|
| Self Care | 1 | 2001 | 97 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2001 | 85 | 0.010 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2001 | 66 | 0.010 |
Why?
|
| Vena Cava, Inferior | 1 | 2000 | 28 | 0.010 |
Why?
|
| Liver Circulation | 2 | 1990 | 7 | 0.010 |
Why?
|
| Research | 1 | 2000 | 81 | 0.010 |
Why?
|
| Trypsinogen | 1 | 1997 | 1 | 0.010 |
Why?
|
| Carboxypeptidase B | 1 | 1997 | 1 | 0.010 |
Why?
|
| Rh-Hr Blood-Group System | 1 | 1996 | 5 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 1996 | 128 | 0.010 |
Why?
|
| Graft vs Host Disease | 1 | 1996 | 39 | 0.010 |
Why?
|
| Enterostomy | 1 | 1995 | 4 | 0.010 |
Why?
|
| Somatostatin | 1 | 1995 | 11 | 0.010 |
Why?
|
| Proteins | 1 | 1997 | 149 | 0.010 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 1995 | 9 | 0.010 |
Why?
|
| Linear Models | 1 | 1996 | 425 | 0.010 |
Why?
|
| Hydronephrosis | 1 | 1994 | 12 | 0.010 |
Why?
|
| Ureteral Obstruction | 1 | 1994 | 28 | 0.010 |
Why?
|
| Cytokines | 1 | 1995 | 237 | 0.010 |
Why?
|
| Venae Cavae | 1 | 1994 | 3 | 0.010 |
Why?
|
| Polyglactin 910 | 1 | 1994 | 6 | 0.010 |
Why?
|
| Azo Compounds | 1 | 1993 | 4 | 0.010 |
Why?
|
| Arginine | 1 | 1993 | 23 | 0.010 |
Why?
|
| Hepatitis | 1 | 1993 | 9 | 0.010 |
Why?
|
| Frozen Sections | 1 | 1993 | 19 | 0.010 |
Why?
|
| Renal Artery Obstruction | 1 | 1994 | 38 | 0.010 |
Why?
|
| Adsorption | 1 | 1993 | 6 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 1993 | 63 | 0.010 |
Why?
|
| Ureter | 1 | 1994 | 39 | 0.010 |
Why?
|
| Aorta | 1 | 1994 | 125 | 0.010 |
Why?
|
| Fibrosis | 1 | 1993 | 126 | 0.010 |
Why?
|
| HLA-DR Antigens | 1 | 1993 | 7 | 0.010 |
Why?
|
| Fatty Liver | 1 | 1993 | 70 | 0.010 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 1992 | 7 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 1995 | 757 | 0.010 |
Why?
|
| Jaundice | 1 | 1992 | 5 | 0.010 |
Why?
|
| Cholangitis | 1 | 1992 | 4 | 0.010 |
Why?
|
| Communicable Diseases | 1 | 1993 | 17 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 1992 | 23 | 0.010 |
Why?
|
| Bile Duct Diseases | 1 | 1992 | 10 | 0.010 |
Why?
|
| Aspartate Aminotransferases | 1 | 1992 | 29 | 0.010 |
Why?
|
| Liver Abscess | 1 | 1992 | 2 | 0.010 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 1992 | 6 | 0.010 |
Why?
|
| Ileal Diseases | 1 | 1991 | 2 | 0.010 |
Why?
|
| Jejunal Diseases | 1 | 1991 | 2 | 0.010 |
Why?
|
| Colonic Diseases | 1 | 1991 | 5 | 0.010 |
Why?
|
| Arterial Occlusive Diseases | 1 | 1992 | 37 | 0.010 |
Why?
|
| Aircraft | 1 | 1991 | 6 | 0.010 |
Why?
|
| Syndrome | 1 | 1991 | 66 | 0.010 |
Why?
|
| Blood Coagulation Disorders | 1 | 1991 | 11 | 0.010 |
Why?
|
| Organ Size | 1 | 1992 | 221 | 0.010 |
Why?
|
| Hypertension, Portal | 1 | 1991 | 10 | 0.010 |
Why?
|
| Catheterization, Peripheral | 1 | 1991 | 27 | 0.010 |
Why?
|
| Candidiasis | 1 | 1991 | 6 | 0.010 |
Why?
|
| Discriminant Analysis | 1 | 1991 | 20 | 0.010 |
Why?
|
| Amphotericin B | 1 | 1991 | 12 | 0.010 |
Why?
|
| Aspergillosis | 1 | 1991 | 9 | 0.010 |
Why?
|
| Surgical Procedures, Operative | 1 | 1992 | 79 | 0.010 |
Why?
|
| Adenoma, Bile Duct | 1 | 1990 | 1 | 0.010 |
Why?
|
| Bile Duct Neoplasms | 1 | 1990 | 33 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 1992 | 164 | 0.000 |
Why?
|
| Prostatic Neoplasms | 1 | 1995 | 489 | 0.000 |
Why?
|
| Protozoan Infections | 1 | 1990 | 1 | 0.000 |
Why?
|
| Spasm | 1 | 1989 | 6 | 0.000 |
Why?
|
| Graft Occlusion, Vascular | 1 | 1989 | 22 | 0.000 |
Why?
|
| Catecholamines | 1 | 1989 | 17 | 0.000 |
Why?
|
| Vasoconstriction | 1 | 1989 | 42 | 0.000 |
Why?
|
| Blood Flow Velocity | 1 | 1989 | 78 | 0.000 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1989 | 70 | 0.000 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 1989 | 4 | 0.000 |
Why?
|
| Minnesota | 1 | 1989 | 19 | 0.000 |
Why?
|
| Ultrasonics | 1 | 1988 | 22 | 0.000 |
Why?
|
| Albumins | 1 | 1989 | 42 | 0.000 |
Why?
|
| California | 1 | 1989 | 61 | 0.000 |
Why?
|
| Immunization | 1 | 1988 | 38 | 0.000 |
Why?
|
| Hematocrit | 1 | 1988 | 20 | 0.000 |
Why?
|
| Pancreatic Function Tests | 1 | 1987 | 1 | 0.000 |
Why?
|
| Prevalence | 1 | 1990 | 955 | 0.000 |
Why?
|
| Methods | 1 | 1987 | 12 | 0.000 |
Why?
|
| Pregnancy | 1 | 1989 | 961 | 0.000 |
Why?
|
| Disease Models, Animal | 1 | 1989 | 1083 | 0.000 |
Why?
|
| Blood Volume | 1 | 1984 | 9 | 0.000 |
Why?
|
| Skin Transplantation | 1 | 1984 | 50 | 0.000 |
Why?
|
| Hemorrhage | 1 | 1984 | 95 | 0.000 |
Why?
|